Compared side by side
Eloralintide vs petrelintide: how they differ
The short answer
Both are weekly amylin drugs in phase 3: eloralintide, from Eli Lilly, is built to act on the amylin receptor more selectively than cagrilintide and lasts about 14 days, and petrelintide, from Zealand Pharma and Roche, is a long-acting amylin analogue that lasts about 10 days. Neither is approved anywhere. In phase 2, eloralintide’s average weight loss ran from about 9.5% on 1 mg to about 20% on 9 mg at 48 weeks, and petrelintide’s reached up to about 10.7% by week 42.
Side by side
| Compared | Eloralintide | Petrelintide |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | LY3841136, Elora | ZP8396, Petre |
| What it is | A once-weekly amylin drug from Eli Lilly, built to copy the fullness hormone the pancreas releases with insulin, and to act on its receptor more selectively than cagrilintide does. | A once-weekly amylin drug from Zealand Pharma and Roche, a long-acting copy of the fullness hormone the pancreas releases with insulin. |
| How it works | Once-weekly, long-acting agonist of the amylin receptor, the receptor for amylin, the fullness hormone the pancreas releases with insulin. Unlike cagrilintide, it is selective: it acts far more on amylin receptors than on the calcitonin receptor, a difference Lilly thinks may make it easier on the stomach. The idea is fewer calories through earlier fullness after meals rather than through the GLP-1 pathway. Its half-life of about 14 days keeps blood levels nearly flat across the week. Investigational, from Eli Lilly, in phase 3 since late 2025. | Long-acting analogue of human amylin, the fullness hormone the pancreas releases with insulin. Amylin receptor activation is thought to make the body more responsive to leptin, its satiety signal, so people feel full sooner. A fatty-acid chain binds it to albumin in the blood, giving a half-life of about 10 days. Zealand designed it to stay stable at neutral pH so it can be mixed with other peptides, and Roche is testing it with its own GLP-1 drug. Investigational, in phase 3 since September 2026. |
| Commonly reported | In trials, fewer cravings, especially for sugar, and less food noise, with nausea and tiredness more likely on the higher doses. It is in phase 3 and not approved anywhere. | Feeling full sooner and smaller portions. It is in phase 3 and not approved anywhere. |
| Studied range | Research range: 1–9 mg, starting dose 3 mg. Studied in research — not a recommendation. | Research range: 1–9 mg, starting dose 0.6 mg. Studied in research — not a recommendation. |
| How often | Weekly | Weekly |
| Half-life | ~14 days (measured in people: phase 1 trials, Bhattachar 2026) | ~10 days (measured in people: mean 213–257 h after SubQ doses, 239 h IV; Brændholt Olsen 2026) |
| Route | SubQ injection | SubQ injection |
| Typical run | Used continuously, once weekly, in its trials: 12 weeks in phase 1 and 48 weeks in phase 2; phase 3 runs about 75 weeks. No trial has tested stopping it. | Used continuously, once weekly, in its trials: 42 weeks in ZUPREME-1 and 28 weeks in ZUPREME-2, with steps every 4 weeks. No trial has tested stopping it. |
| Evidence | Moderate: animal studies + some human data | Moderate: animal studies + some human data |
| Common side effects | Nausea, fatigue, constipation, diarrhea, vomiting, decreased appetite, hair thinning, injection site reaction | Nausea, decreased appetite, constipation, diarrhea |
- Category
- EloralintideMetabolic & GLP-1
- PetrelintideMetabolic & GLP-1
- Also known as
- EloralintideLY3841136, Elora
- PetrelintideZP8396, Petre
- What it is
- EloralintideA once-weekly amylin drug from Eli Lilly, built to copy the fullness hormone the pancreas releases with insulin, and to act on its receptor more selectively than cagrilintide does.
- PetrelintideA once-weekly amylin drug from Zealand Pharma and Roche, a long-acting copy of the fullness hormone the pancreas releases with insulin.
- How it works
- EloralintideOnce-weekly, long-acting agonist of the amylin receptor, the receptor for amylin, the fullness hormone the pancreas releases with insulin. Unlike cagrilintide, it is selective: it acts far more on amylin receptors than on the calcitonin receptor, a difference Lilly thinks may make it easier on the stomach. The idea is fewer calories through earlier fullness after meals rather than through the GLP-1 pathway. Its half-life of about 14 days keeps blood levels nearly flat across the week. Investigational, from Eli Lilly, in phase 3 since late 2025.
- PetrelintideLong-acting analogue of human amylin, the fullness hormone the pancreas releases with insulin. Amylin receptor activation is thought to make the body more responsive to leptin, its satiety signal, so people feel full sooner. A fatty-acid chain binds it to albumin in the blood, giving a half-life of about 10 days. Zealand designed it to stay stable at neutral pH so it can be mixed with other peptides, and Roche is testing it with its own GLP-1 drug. Investigational, in phase 3 since September 2026.
- Commonly reported
- EloralintideIn trials, fewer cravings, especially for sugar, and less food noise, with nausea and tiredness more likely on the higher doses. It is in phase 3 and not approved anywhere.
- PetrelintideFeeling full sooner and smaller portions. It is in phase 3 and not approved anywhere.
- Studied range
- EloralintideResearch range: 1–9 mg, starting dose 3 mg. Studied in research — not a recommendation.
- PetrelintideResearch range: 1–9 mg, starting dose 0.6 mg. Studied in research — not a recommendation.
- How often
- EloralintideWeekly
- PetrelintideWeekly
- Half-life
- Eloralintide~14 days (measured in people: phase 1 trials, Bhattachar 2026)
- Petrelintide~10 days (measured in people: mean 213–257 h after SubQ doses, 239 h IV; Brændholt Olsen 2026)
- Route
- EloralintideSubQ injection
- PetrelintideSubQ injection
- Typical run
- EloralintideUsed continuously, once weekly, in its trials: 12 weeks in phase 1 and 48 weeks in phase 2; phase 3 runs about 75 weeks. No trial has tested stopping it.
- PetrelintideUsed continuously, once weekly, in its trials: 42 weeks in ZUPREME-1 and 28 weeks in ZUPREME-2, with steps every 4 weeks. No trial has tested stopping it.
- Evidence
- EloralintideModerate: animal studies + some human data
- PetrelintideModerate: animal studies + some human data
- Common side effects
- EloralintideNausea, fatigue, constipation, diarrhea, vomiting, decreased appetite, hair thinning, injection site reaction
- PetrelintideNausea, decreased appetite, constipation, diarrhea
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Eloralintide
- Day 1–28 · 3 mg Fullness first, gently
- Day 29–56 · 6 mg The step where nausea shows up
- Day 57–336 · 6 mg Holding at 6 mg
- Day 57–336 · 9 mg The top dose tested
- Day 85–336 Fewer cravings, quieter food noise
- Day 337+ A long-term medicine, not a course
Petrelintide
- Day 1–28 Fullness, gently
- Day 29–294 · 2.5 mg Low doses already work
- Day 57–294 · 5 mg Five milligrams
- Day 85–294 · 9 mg The top dose tested
- Day 85–294 With type 2 diabetes
- Day 197–294 Weeks 28 to 42: still moving
Questions people ask
How long do eloralintide and petrelintide last?
The half-life of eloralintide is ~14 days (measured in people: phase 1 trials, Bhattachar 2026). The half-life of petrelintide is ~10 days (measured in people: mean 213–257 h after SubQ doses, 239 h IV; Brændholt Olsen 2026).
How often are eloralintide and petrelintide taken?
Eloralintide: weekly. Route: SubQ injection. Petrelintide: weekly. Route: SubQ injection.
How are eloralintide and petrelintide dosed in research?
The research range for eloralintide is 1–9 mg, with a 3 mg starting dose. The research range for petrelintide is 1–9 mg, with a 0.6 mg starting dose. Studied in research — not a recommendation.
What are the common side effects of eloralintide and petrelintide?
For eloralintide, the library lists: nausea, fatigue, constipation, diarrhea, vomiting, decreased appetite, hair thinning, injection site reaction. For petrelintide: nausea, decreased appetite, constipation, diarrhea.